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Abstract
In this thesis, the control of hypertension provides the backdrop for my effort to investigate how
clinical trial design has evolved for antihypertensive drug submissions reviewed and approved by the
Food and Drug Administration between 1988 and 2001. To do this, I have constructed and undertaken a
preliminary analysis of a number of quantitative surrogate measures of complexity and scale, such as trial
design, numbers of patients, treatment lengths, active drug comparators, number of indications pursued,
number of indications approved, and approval times. In addition, I review how practice guidelines for
the treatment of hypertension have changed with advancing clinical and biological knowledge. I attempt
to investigate whether a link exists between the changing characteristics of clinical trials for
antihypertensive therapies and the evolving guidelines for treating hypertension, promulgated by the
Joint National Committee Report on the Detection, Evaluation, and Treatment of High Blood Pressure,
(JNC), a committee assembled by the National Heart, Lung, and Blood Institute.
Although the number of New Drug Applications (NDAs) examined in the antihypertensive class
is too small to permit rigorous statistical analyses, I am nonetheless able to observe a number of apparent
trends within the set of NDA submissions for antihypertensives approved by the FDA. Specific trends I
observe in support of increasing trial complexity include: 1) trial sizes increase over time as measured by
patient enrollments per trial (p-value = 0.003); 2) clinical trial designs over time have included greater
numbers of arms per trial (p-value = 0.022); and 3) the number of drug-drug interaction studies in
antihypertensive NDAs has increased with time (p-value = 0.027). These trends offer preliminary support
for the hypothesis that clinical trials associated with NDA applications for antihypertensives have
become more complex over the last two decades.
The mechanisms responsible for the observed increase in complexity are less clear. Based on
available information, I cannot determine if FDA guidance documents or informal correspondence were
responsible for making antihypertensive clinical trials more complicated, or whether pharmaceutical
companies introduced greater complexity into the trial design for commercial reasons. Furthermore,
while I observe that FDA guidelines did not precisely track changes in JNC guidelines for treating
hypertension, it is not clear whether the discrepancies are meaningful. Future research might attempt to
identify more precisely the causes of increasing clinical trial complexity, and attempt to relate trial
complexity to the cost of drug development more generally.
Thesis Supervisor: Ernst R. Berndt
Title: Louis E. Seley Professor in Applied Economics
-3-
Acknowledgments
Completing this thesis and course of study would not have been possible without the help,
support, and guidance of my research advisor, Professor Ernst Berndt. I also owe a debt of gratitude to
my colleague Hsiao-Lan (Sharon) Lin, whose advice and companionship helped make the effort
enjoyable.
I appreciate the assistance of the members of the FDA/MIT research team, who helped make this
thesis possible. From MIT: Dr. Frank Douglas, Mark Trusheim, Melissa Dere, Jean Kim, and Dr. Fabio
Thiers. From FDA: Randall Lutter, Ilisa Bernstein, and Don Banks.
I would like to thank my parents Nicholas and Linda MacNeil, and my sisters Marcia and Laura
MacNeil, for their love and moral support.
-4-
Table of Contents
1. Introduction 10
1.1 Motivation and Objective 10
1.2 Pharmaceutical Industry R&D Spending and Productivity 10
1.3 Thesis Organization 14
2. Hypertension 14
2.1 Definition of Hypertension 14
2.2 Summary of Medical Condition (Hypertension) 15
2.3 Treatment of Hypertension Prior to JNC IV 18
2.4 JNC IV to JNC VI 21
2.5 JNC VI to JNC VII 25
2.6 Hypertension in African-Americans 28
3. Clinical Trials 29
3.1 Attributes of Phase I-III Clinical Trials 29
3.2 Principles of Phase III Clinical Trial Design 31
4. Research Methodology 33
4.1 Description of FDA Action Package 33
4.2 Hypotheses 36
5. Results and Discussion 36
5.1 Summary of the Data 37
5.2 Increase in Patients per Pivotal Trial 38
5.3 Trends in Number of Pivotal Trials per NDA 41
5.4 Trends in Number of Arms per Pivotal Trial 42
5.5 Increase in Drug-Drug Interaction Studies over Time 45
5.6 Trends in Patient Drop-out Rates 47
5.7 Decreasing Time to Approval 49
6. Inclusion/Exclusion Criteria 50
7. Conclusion and Limitations 52
8. Policy Implications 53
8.1 FDA Guidance and JNC Treatment Recommendations 53
8.2 Is FDA Responsible for the Increasing Complexity of Clinical Trials? 55
Appendix I: Summary of Blood Pressure Classification Schemes (JNC III through JNC VII) 61
Appendix II: Summary of Major Hypertension Therapy Clinical Studies (JNC III-VII) 62
Appendix III: Regression Analysis Results 66
Appendix IV: Example of Inclusion/Exclusion Criteria for a Clinical Trial 82
References 83
-5-
Glossary
ACE inhibitor: An angiotensin-converting enzyme (ACE) inhibitor is a member of an antihypertensive
drug subclass that interferes with the renin-angiotensin-aldosterone system by inhibiting the enzyme
dipeptidase A, which is responsible for hydrolyzing the hormone angiotensin I into angiotensin II.
Action Package: a dossier held by the FDA that contains all information relevant to the agency's review
of a New Drug Application (NDA) or Biologic License Application (BLA). In its electronic form, the
Action Package is a set of PDF files containing scanned-in documents of FDA reviews, notes to the file,
and memos of meetings.
active control trial: a type of clinical trial design that randomizes one group of patients to receive the new
drug (the subject of the study) and another group of patients to receive an existing treatment or drug, as a
means of comparing the effect of the new and existing therapies
ALLHAT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
was the largest antihypertensive trial and the second largest lipid-lowering trial and included large
numbers of patients over age 65, women, African-Americans, and patients with diabetes, treated largely
in community practice settings.
a-blocker: Alpha adrenegic receptor blockers, or a-blockers, make up an antihypertensive drug subclass
that inhibits al-receptors on catecholamines in arterioles and venules, allowing the hormone
norepinephrine to stimulate vasodilation, thereby lowering blood pressure.
angiotensin II: A hormone derived from renin, which is produced in the liver. Angiotensin II acts to
increase blood pressure by constricting arterioles and prompting the release of aldosterone, a hormone
that simulates the kidneys to retain more salt and water in the bloodstream.
antianginal: used or tending to prevent or relieve angina pectoris, a disease characterized by paroxysmal
attacks of substernal pain of short duration
antiarrhythmic: counteracting or preventing cardiac arrhythmia, an alteration in the rhythm of the
heartbeat either in time or force that is of functional or organic origin
arm: An arm of a trial is any discrete group of patients randomized at the beginning of the study to
undergo treatment different from the other randomized groups.
3-blocker: A beta adrenergic receptor blocker, or P-blocker, is a member of an antihypertensive drug
subclass that inhibits the stimulation of renin production by interfering with the beta adrenoceptors on
catecholamines.
bioavailability: the degree and rate at which a substance (as a drug) is absorbed into a living system or is
made available at the site of physiological activity
BLA: A Biologic License Application (BLA) must be submitted to the FDA for pre-market approval of
biologic therapeutics, as defined by the Public Health Service Act.
BMI: Body Mass Index
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calcium channel blocker: a subclass of antihypertensive drug that inhibits the transport of Ca2+ into the
cytoplasm of arterial smooth muscle cells
catecholamine: a class of neurotransmitters involved in the sympathetic nervous system.
diastolic blood pressure: the blood pressure in the body measured during the period just before the heart
begins to contract again (known as diastole)
diuretic: a subclass of antihypertensive drug that promotes the body's excretion of water, either via: 1)
the excretion of sodium and chloride in the urine (thiazide diuretic); 2) inhibiting the kidney's ability to
reabsorb sodium, thus enhancing the loss of sodium in the urine (loop diuretic); or 3) blocking the
exchange of sodium for potassium, resulting in excretion of sodium and potassium but relatively little
loss of potassium (potassium sparing diuretic)
Division File System (DFS): an electronic file system used by the FDA's Center for Drug Evaluation and
Research (CDER) to manage and distribute internal documents
drug-drug interaction: To determine whether an investigational new drug has the potential to interfere
with the body's ability to metabolize or excrete other drugs that a patient may be taking concurrently, the
FDA often requires that sponsors undertake drug-drug interaction studies.
epinephrine: the principal blood-pressure-raising hormone of the medulla of the adrenal glands,
prepared from adrenal extracts and also synthetically, and used chiefly as a heart stimulant, as a
vasoconstrictor in controlling hemorrhages of the skin and in prolonging the effects of local anesthetics
equivalence trial: a clinical trial design in which patients are randomized into arms comparing a new and
existing drug in an attempt to establish that the new drug is neither worse than nor better than the
existing therapy
FDA guidance: Guidance documents represent the Food and Drug Administration's current thinking on
a particular subject. An alternative approach may be used if such approach satisfies the requirements of
the applicable statute or regulations.
inclusion/exclusion criteria: The medical or social standards determining whether a person may or may
not be allowed to enter a clinical trial. These criteria are based on such factors as age, gender, the type and
stage of a disease, previous treatment history, and other medical conditions.
JNC: Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. The
committee came into existence as an offshoot of the National High Blood Pressure Education Program
(NHBPEP), a program established by the National Heart, Lung, and Blood Institute in 1972 to increase
"awareness, prevention, treatment, and control of hypertension." The JNC committee consisted of
representatives from most of the major medical organizations, a broad array of academic medical
researchers, and officials from other Federal agencies with public health responsibilities.
labile hypertension: Labile hypertension is blood pressure that fluctuates abruptly and repeatedly, often
causing symptoms such as headache or ringing in the ears.
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Medical Review: a review of a New Drug Application (NDA) performed by qualified personnel at FDA
for the purpose of critiquing trial design and conduct, summarizing and critiquing applicant's analyses,
selectively verifying applicant's findings, summarizing risks and benefits, and making a recommendation
as to whether the NDA should be approved
NDA: a New Drug Application (NDA) is the vehicle through which drug sponsors formally propose that
the FDA approve a new pharmaceutical for sale and marketing in the US. The documentation required in
an NDA is supposed to tell the drug's whole story, including what happened during the clinical tests,
what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body,
and how it is manufactured, processed and packaged.
new molecular entity (NME): refers to a drug that contains no active moiety that has been approved by
FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic
Act.
norepinephrine: a hormone that occurs with epinephrine, has a strong vasoconstrictor action, and
mediates transmission of sympathetic nerve impulses. However, it lacks or exhibits weakly most other
epinephrine effects (as on cardiac output or blood-sugar concentration)
ouabain: an endogenous hormone synthesized in the adrenal gland
phase I trial: initial studies to determine the metabolism and pharmacologic actions of drugs in humans,
the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include
healthy participants and/or patients
phase II trial: controlled clinical studies conducted to evaluate the effectiveness of the drug for a
particular indication or indications in patients with the disease or condition under study and to
determine the common short-term side effects and risks
phase III trial: expanded controlled and uncontrolled trials after preliminary evidence suggesting
effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate
the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling
pivotal trials: the set of phase III trials that the FDA considers most significant for determining whether
the sponsor has demonstrated that the study drug is safe and effective
placebo controlled trial: A method of investigation of drugs in which an inactive substance (the placebo)
is given to one group of participants, while the drug being tested is given to another group. The results
obtained in the two groups are then compared to see if the investigational treatment is more effective in
treating the condition.
primary endpoint: the most important overall outcome that the clinical trial protocol is designed to
evaluate
randomized trial: A study in which participants are randomly (i.e., by chance) assigned to one of two or
more treatment arms of a clinical trial.
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renin: a proteolytic enzyme that is found in the kidney and that leads to the production of the hormone
angiotensin II
renin-angiotensin-aldosterone system: a biochemical pathway closely associated with the
pathophysiology of hypertension because it can increase cardiac output and total peripheral vascular
resistance
secondary endpoint: other outcomes (of secondary importance to the primary endpoint) that contribute
to the interpretation of a clinical trial
stepped-care regimen: a course of treatment that starts with the drugs of lowest toxicity and adds drugs
from other groups as needed. This permits the use of less toxic agents in mild and responsive cases, with
the more powerful (and toxic) agents reserved for use in severe disease.
sphygmomanometer: an inflatable cuff attached to a device for measuring a patient's blood pressure
Statistical Review: a review performed by qualified FDA statisticians to evaluate the statistical relevance
of the data in the NDA, with the main tasks of evaluating the methods used to conduct studies and the
various methods used to analyze the data. The purpose of these evaluations is to give the medical officers
a better idea of the power of the findings to be extrapolated to the larger patient population.
sympathetic nervous system: a branch of the autonomic nervous system that is always active at a basal
level (called sympathetic tone) and becomes more active during times of stress. Its actions during the
stress response comprise the fight-or-flight response.
systolic: the blood pressure in the body measured in the arteries during the heart's contraction (known as
systole)
vasodilator: an agent (as a parasympathetic nerve fiber or a drug) that induces or initiates vasodilation,
the widening of the lumen of blood vessels
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Chapter 1: Introduction
1.1 Motivation and Objective
Studying the changing nature of clinical trial design has the potential to shed light on the much-
publicized increases over time in the costs of drug development and the decline in R&D productivity of
the pharmaceutical industry. One plausible explanation for a more expensive drug development process
is that the complexity and scale of clinical trials have increased over the past 20 years. This thesis presents
portions of one in a series of studies by a team of MIT students, MIT-HST faculty, and FDA officials
examining the changing characteristics of New Drug Application (NDA) submissions reviewed and
approved by the FDA in a number of therapeutic areas. Facilitated by a Memorandum of Understanding
between the FDA and MIT, FDA Action Package Reviewers' summaries along with NDA publicly
available data have been analyzed to explore what changes over time can be observed in the
characteristics of clinical trials.
Learning about how clinical trials have changed over time could also lead to new insights into
whether or to what extent clinical treatment guidelines are reflected in the design of clinical trials to
assess the safety and efficacy of new drugs to treat a particular medical condition. This thesis describes
how practice guidelines for the treatment of hypertension have changed with advancing clinical and
biological knowledge. I attempt to investigate whether a link exists between the changing characteristics
of clinical trials for antihypertensive therapies and the evolving guidelines for treating hypertension,
promulgated by the Joint National Committee Report on the Detection, Evaluation, and Treatment of
High Blood Pressure, (JNC), a committee assembled by the National Heart, Lung, and Blood Institute. To
do this, I have constructed and undertaken a preliminary analysis of a number of quantitative surrogate
measures of complexity and scale, such as trial design, numbers of patients, treatment lengths, active
drug comparators, number of indications pursued, number of indications approved, and approval times.
1.2 Pharmaceutical Industry R&D Spending and Productivity
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Before charging headlong into the changes in clinical trials for antihypertensives, to provide
context I consider other potential causes for the increase in R&D spending by the pharmaceutical
industry and the simultaneous trend toward declining productivity in terms of innovative new drugs.
First, it is clear the absolute value of R&D spending in the pharmaceutical sector is large. One
widely cited estimate for the average cost of developing an innovative new drug puts the cost at more
than $800 million, and the average time required to develop an innovative new drug at about 12 years.'
One must be clear, of course, by what we mean by "average cost of developing an innovative new drug."
Included in this estimate is the cost of all the failed drug compounds the pharmaceutical company, or
drug sponsor, must go through before landing upon a compound that successfully reaches the market. In
addition, a sponsor's actual expenditures make up only about half of the total estimated cost. This is
because there is a financial cost to tying up capital in years-long drug development projects that earn no
return unless and until the drug is able to reach the market (if the capital had not been tied up in testing
the new drug, it could have been used to earn a higher return elsewhere). The opportunity cost of capital
is particularly pronounced in the pharmaceutical industry given the 12 years, on average, required to
develop a new drug.2
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Figure 1: Research and Development Spending and Productivity for Various US Industries3
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As shown above in Figure 1, R&D spending on drugs has risen with respect to R&D spending in
the communications and computing sectors, while drug R&D productivity has dropped in comparison to
productivity in these two fields.* A report completed in October 2006 by the Congressional Budget Office
(CBO) found several potential explanations for the estimated 7.4 percent rise (above inflation) in average
R&D costs during the 1980s, and the 9.4 percent rise (above inflation) during the 1970s. 4
As its first plausible explanation for the continuing growth in R&D costs for innovative new
drugs, the CBO report describes the increase in the percentage of drug projects that fail in clinical trials.
According to the FDA, the proportion of all new drugs entering phase I trials that ultimately gain
approval has fallen to 8 percent from a historical average of about 14 percent.5 The later these failures
occur in the drug development process, the more significant the effect on the average cost of developing a
successful therapeutic.
This figure measures productivity as the number of patents granted in an industry per dollar of research and
development spending. R&D spending in one year is compared with successful patents two years later, reflecting the
lag with which such spending leads to patent applications.
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The CBO report also proposes that rising R&D costs could be attributed to the cost of performing
clinical trials. According to an estimate by DiMasi et al, average clinical phase costs grew fivefold between
1987 and 2000, or at an average rate of more than 12 percent per year in real terms, due to increases in the
size and duration of clinical trials.6 The DiMasi et al study also estimates that the average number of
people per trial grew by 7.5 percent annually, from about 2,300 in the 1980s to more than 5,600 by the
early 2000s. In a separate study DiMasi found that the average length of the clinical trial phase increased
by 27 percent over the 1980s and then declined by 4 percent over the 1990s.7 The CBO report suggests
that sponsors may be motivated to perform clinical trials for marketing and product differentiation
purposes, by comparing their drug with a competitor's in addition to a placebo (for the purposes of
approving an NDA, FDA requires only that sponsors establish that their new drug is safe and efficacious
in comparison to a placebo). However, including a head-to-head comparison with a competitor's drug
will often require a larger and more costly clinical trial because differences in efficacy will be less
pronounced than just between the drug and placebo.
Another potential explanation for rising drug R&D costs could be pharmaceutical sponsors'
heightened focus on developing drugs for chronic and degenerative diseases rather than acute illnesses.
Such drugs, which are meant to be taken by patients for a long time, increase the potential for financial
returns should the drug be approved, but in the short run drugs for chronic diseases are more expensive
to test in clinical trials because they may take longer to show statistically meaningful results. Clinical
trials for such drugs may also require more vigilant monitoring for long-term side effects, further
boosting the cost of the studies.
In addition, the CBO report points to advances in basic research that may have boosted R&D
costs in the short run, but not yet induced the desired upswing in output of innovative new drugs. Many
researchers predicted that new technologies such as genomics and proteomics would uncover biological
insights that would rapidly lead to new drugs; instead, scientists discovered that translating biological
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understanding into improvements in the efficiency of drug discovery and development is not trivial.
Such learning costs could be partly responsible for lowering research output and raising costs. Lastly, the
CBO report cites the increase in universities' total royalty income on patents (much of which are
biomedical in nature) as evidence that more pharmaceutical sponsors are having to pay for access to basic
research findings that in previous years might have been in the public domain.8
The foregoing discussion of potential sources for the growth in R&D spending should provide
the reader with an understanding of the context for the subject of this thesis. However, it is important to
stress that this thesis does not attempt to link changes in the complexity of clinical trials with their impact
on the cost of clinical trials. Such an investigation would require estimates of the marginal cost per patient,
and marginal cost per arm of a study, among other factors. Obtaining the information necessary to
formulate these estimates would be challenging, given its proprietary nature, and is beyond the bounds
of the current Master's thesis. In other words, the research described in the thesis focuses only on what
the results purport to say about whether clinical trials have become more complicated or not.
1.3 Thesis Organization
The outline of the thesis is as follows. In Chapter 2, I provide an overview of the etiology of
hypertension, and describe how treatment guidelines for the disease have evolved over time -
concurrently with the development of new antihypertensive drugs. Chapter 2 also includes a brief
discussion of how ethnicity has played a role in guidelines for treating hypertension. In Chapter 3, I
provide an overview of the drug development process and introduce several general principles of clinical
trial design. In Chapter 4 I present my research methodology, in Chapters 5 and 6 I discuss and interpret
the results of the research, and in Chapter 7 I1 lay out conclusions and limitations to the analysis. Lastly, in
Chapter 8 I1 provide policy context and discussion.
Chapter 2: Hypertension
2.1 Definition of Hypertension
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Hypertension, or abnormally high pressure in the arteries, is a condition common in the
developed world and is becoming increasingly common in developing countries - in fact, about 20
percent of the world's adult population is estimated to be hypertensive.9 Because hypertension has been
shown to increase a patient's risk for cerebrovascular and ischemic heart disease, 10 the condition has
attracted considerable interest from the medical community, particularly pharmaceutical companies,
which have produced a steady supply of new treatments over the past few decades to help control high
blood pressure. In this paper, the control of hypertension provides the backdrop for my effort to
investigate how clinical trial design has evolved for antihypertensive drug submissions reviewed and
approved by the Food and Drug Administration between 1988 and 2001.
2.2 Summary of Medical Condition (Hypertension)
In medical[ terms, hypertension is defined with the use of two measurements: systolic blood
pressure and diastolic blood pressure. Using a sphygmomanometer (an inflatable cuff attached to a
measurement device), healthcare providers measure the blood pressure in the arteries during the heart's
contraction (known as systole), and also during the period just before the heart begins to contract again
(known as diastole). Blood pressure is highest during systole, and lowest during diastole. Thus, when
reporting a patient's blood pressure, physicians record the ratio of two values: systolic blood pressure
over diastolic pressure. Normal blood pressure, as defined by the most recent JNC report, corresponds to
a systolic blood pressure below 120 mm Hg, and a diastolic blood pressure below 80 mm Hg, or 120/80.
As shown in Figure 2, the last 40 years have seen median and 90th percentile blood pressures shift
downward over time, according to data collected from a sequence of National Health and Nutrition
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Figure 2: Smoothed Weighted Frequency Distribution, Median, and 90t Percentile of Systolic Blood
Pressure for Ages 60-74 Years: United States, 1960-199111
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Examination Survey (NHANES) studies, a program of studies that combines interviews and physical
examinations to assess the health and nutritional status of adults and children in the United
States. Between the periods of 1976-1980 and 1999-2000, NHANES data show that the percentage of
patients with hypertension receiving treatment has increased from 31 percent to 59 percent, and the
percentage of people with high blood pressure controlled to below 140/90 mm Hg has increased from 10
percent to 34 percent. 12 Nonetheless, control rates for hypertension in the US are far from optimal.
With respect to etiology, the exact causes of hypertension are unclear. Heredity is a strong
predisposing factor, and environmental factors such as obesity, a high-salt diet, and stress can exacerbate
this predisposition. In a recent study investigating the effect of antihypertensive therapy on morbidity
and mortality, Long et al. identified the following relative risk factors for hypertension: high body mass
index (BMI), diabetes, family history, excessive alcohol use, high salt diet, exercise, race, age and sex.13
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The body has several mechanisms for regulating blood pressure. The sympathetic nervous
system, which controls internal body processes, can increase or decrease blood pressure by regulating the
body's release of the hormones epinephrine and norepinephrine (a common example of when this occurs
is during the fight-or-flight response). These hormones stimulate the heart to beat more rapidly and more
powerfully, and for most arterioles to constrict, resulting in greater blood pressure. The sympathetic
nervous system can also prompt the kidneys to eliminate less salt and water from the bloodstream, with
the resulting increase in blood volume leading to higher blood pressure.
The kidneys also act separately to help regulate blood pressure. In addition to controlling the
amount of salt and water excreted from the blood stream, which affects blood volume, the kidneys can
increase blood pressure by releasing the enzyme renin, which leads to the body's production of the
hormone angiotensin II. This hormone acts to increase blood pressure by constricting arterioles and
prompting the release of aldosterone, a hormone that stimulates the kidneys to retain more salt and water
in the bloodstream. This biochemical mechanism, known as the renin-angiotensin-aldosterone system, is
closely associated with the pathophysiology of hypertension because it can increase cardiac output and
total peripheral vascular resistance.14
Another biochemical mechanism involving the intracellular sodium pump has been
hypothesized to explain the etiology of hypertension in some patients. There is evidence that endogenous
ouabain, an adrenal steroid, interacts with the a2 isoform of the sodium pump in vascular muscle cells to
inhibit the pump's function, thereby inducing the Na/Ca exchanger to push more Ca2+ into the cytoplasm
of vascular muscular tissue. Higher levels of intracellular Ca2+ increases the tone and contractility of
smooth vascular muscle, leading to a rise in peripheral vascular resistance and higher blood pressure.15
While the causes of hypertension are still a matter of debate, the implications of the condition are
known and fairly well defined. According to the 17th edition of The Merck Manual, "An untreated
hypertensive is at great risk of disabling or fatal left ventricular failure, MI [myocardial infarction],
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cerebral hemorrhage or infarction, or renal failure at an early age." Hypertension is also an important risk
factor predisposing patients to stroke, and is one of three risk factors (including cigarette smoke and
hypercholesterolemia) associated with increased incidence of coronary atherosclerosis. There is
preliminary evidence that certain types of antihypertensive therapy can increase a patient's risk for
diabetes,16 but the more generally accepted phenomenon is of diabetes and hypertension acting in concert
to increase a patient's risk for cardiovascular disease. 17 Medical treatment can prevent or forestall these
eventualities; nevertheless, coronary artery disease is the most common cause of death for treated
hypertensive patients.'8
2.3 Treatment of Hypertension Prior to JNC IV
Up until the mid to late 1940s, many in the medical profession were confused as to the
significance of high blood pressure. While some physicians realized the potential for later complications
in patients, others saw hypertension as relatively benign. For example, the 1946 edition of Tice's Practice of
Medicine states that "Overzealous attempts to lower the pressure may often do no good and often do
harm." 19 Partly this attitude stemmed from ignorance, and partly from a lack of means to adequately
treat high blood pressure without causing significant side effects in the patient.
Beginning in the late 1940s and early 1950s, however, physicians began to acknowledge the link
between hypertension and cardiovascular disease. For the most severe cases of hypertension physicians
began prescribing low-sodium and low-fat diets, and experimenting with doses of ganglion-blocking
agents, catecholamine depletors, and vasodilators. The relatively crude nature of these pharmaceuticals
for treating high blood pressure limited their use to the most severe sufferers; patients with relatively
mild forms of the disease were often told that complications were unavoidable. 20 In one example of the
nature of antihypertensive therapy at the time, President Franklin Delano Roosevelt, whose blood
pressure began to rise in 1937, was treated with phenobarbital (a sedative used to control epilepsy and
anxiety), a low-fat, low-sodium diet, and rest. Over the next seven years he developed left ventricular
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hypertrophy, congestive heart failure, multiple lacunar infarcts (nonthrombotic occlusion of small, deep
cortical arteries), and renal failure, dying in 1945 of a cerebral hemorrhage at the age of 63.21 As Cutler
points out in Your Money or Your Life,22 a 1948 pamphlet on treating hypertension recommended that
hypertensive patients slow down, and take a rest around midday. The pamphlet, published by the US
Public Health Service, also mentioned a few more drastic therapies for hypertension, including
sympathectomy (severing of the nerves to blood vessels) and pyrogen therapy (inducing fever to lower
blood pressure). 23
After 1958, the advent of diuretics dramatically improved physicians' ability to manage difficult
cases of hypertension. Later, the introduction of a- and p-blockers in the 1960s and 1970s led to the first
large-scale clinical trials to investigate the impact of antihypertensive drugs on patients with milder cases
of the condition, and to perform the first dose-response studies of these agents in patients. By the mid
1970s, physicians had begun experimenting with combinations of various antihypertensives that
appeared to increase patient response and reduce side effects. 24 As shown in Table 1, from the 1940s
through the 1980s the pace of new drug development was rapid.
Table 1: List of Available Antihypertensive Drugs from the 1930s through 199725
1930s Veratrumn alkaloids
1940s Thiocyanates
Ganglion blocking agents
Catecholamine depletors (Rauwolfa derivatives)
1950s Vasodilators (H-ydralazine)
Peripheral sympathetic inhibitors (guanethidine)
Monoamine oxidase inhibitors
Diuretics
1960s Central az-agonists (sympathetic nervous
system inhibitors)
f-Adrenergic inhibitors
1970 a-Adrenergic inhibitors
a-fl-Blockers
Converting enzyme inhibitors
1980s Calcium channel blockers
1990s Angiotensin II (AT1) receptor antagonists
Over the subsequent decades, the Joint National Committee (JNC) on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure issued a series of reports summarizing the evolving
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available scientific evidence, and offering physicians recommended practice guidelines. The content of
this series of JNC reports is summarized in greater detail in Appendix I and Appendix II.
The first Joint National Committee report was designed to provide recommended treatment
guidelines for physicians and their patients. The committee came into existence as an offshoot of the
National High Blood Pressure Education Program (NHBPEP), a program established by the National
Heart, Lung, and Blood Institute in 1972 to increase "awareness, prevention, treatment, and control of
hypertension." 26 The JNC committee consisted of representatives from most of the major medical
organizations, a broad array of academic medical researchers, and officials from other Federal agencies
with public health responsibilities.
The first set of guidelines, issued in the 1977 report, recommended that patients with blood
pressures >160/95 mm Hg have their blood pressure rechecked within a month, but patients over the age
of 50 with this relatively mild degree of hypertension were to be left pretty much alone (at the time
hypertension was considered to be relatively unimportant as a risk factor in that age group). This first
JNC report also introduced the idea of a stepped-care regimen for patients suffering from severe
hypertension, suggesting thiazide diuretics as a first line therapy, with catecholamine depletors
(reserpine), methyldopa, or propranolol to be added if the patient did not respond. A third line of
pharmacological attack included vasodilators (hydralazine), peripheral sympathetic inhibitors
(guanethidine), or clonidine, an alpha 2 agonist.
The next two JNC reports (JNC II and JNC III), issued in 1980 and 1984, recommended thiazide
diuretics and beta blockers as initial therapy, followed by second line therapies similar to that laid out in
the first JNC report of 1977. By 1988, calcium channel blockers and ACE inhibitors had entered the
marketplace (see Table 1), and the JNC IV report added those two classes of drugs as alternatives for
initial therapy along with diuretics and beta blockers. Although there were no long-term morbidity or
mortality outcome data associated with these two new classes of antihypertensives - they had not yet
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been used in long-term clinical trials - it was clear that they were much better tolerated than earlier
antihypertensive drugs such as guanethidine, methyldopa, and clonidine.
2.4 JNC IV to JNC VI
Up to and including the JNC IV report, issued in 1988, the decision to pursue antihypertensive
treatment depended primarily on a patient's diastolic blood pressure (the measurement of pressure as the
heart relaxes to allow the blood to flow into the heart). This preference was due partly to history - the
earliest clinical trials showing the benefits of lowering blood pressure relied on diastolic measurements2 7
- and partly due to an oversight in interpreting the literature. Of interest is a 1959 report in Society of
Actuaries that indicated systolic blood pressure was a better predictor of health outcomes.28
Compounding matters, reports in the literature state that the FDA used diastolic blood pressure as the
basis for its criteria in assessing the efficacy of new antihypertensive medications, 29 at least until the
agency issued new draft guidance in 2000. Today it is widely believed that diastolic blood pressure is a
more potent cardiovascular risk for patients below 50 years of age, but above this age systolic
hypertension is the more important factor.3 0 There are no estimates of the cumulative impact on public
health of past reliance on diastolic rather than systolic blood pressure to determine antihypertensive
treatment, but physicians' focus on diastolic blood pressure as a target seems to have led to less than
optimal control of hypertensives' blood pressure. 31
Specifically, the JNC IV report focused on diastolic blood pressure as an intermediate end point;
it referenced only five prospective, randomized, controlled trials of antihypertensive therapy with end
points of morbidity and mortality, and one trial using congestive heart failure as an end point. (For
descriptions of the major prospective clinical studies relevant to the recommendations in JNC IV through
JNC VII, please see Appendix II). The JNC V report provided additional evidence from four clinical trials
of antihypertensive therapy, pinpointing the effects of antihypertensives on a patient population with
isolated systolic hypertension and a population with mixed systolic and diastolic hypertension. These
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findings foreshadowed the later conclusion in the JNC VI report that systolic blood pressure (the pressure
that blood exerts on the artery walls as the heart contracts to pump out the blood) is a better metric for
treatment recommendations and goals.
By the time JNC issued its fourth report in 1988, the FDA had approved five of the six major
classes of antihypertensive drugs that are still widely prescribed today, as shown in Table 2. On the basis
of mechanism of action, however, each of these drug classes differs markedly from its peers. Diuretics act
on the kidney to increase the amount of sodium eliminated from the bloodstream, thereby reducing
overall blood volume and decreasing blood pressure. Some diuretics, such as indapamide and amiloride,
also exhibit vasodilating effects. Beta adrenergic receptor blocking agents, or beta blockers, inhibit the
stimulation of renin production by interfering with the beta adrenoceptors on catecholamines, a class of
neurotransmitters involved in the sympathetic nervous system. Beta blockers have also been shown to
reduce mortality in patients with heart failure (see Table 2). Alpha adrenergic receptor blockers, in
contrast, inhibit al-receptors on catecholamines in arterioles and venules, allowing norepinephrine to
stimulate vasodilation, thereby lowering blood pressure. Besides having antianginal and antiarrhythmic
effects, calcium channel blockers also dilate peripheral arterioles by inhibiting the transport of Ca2+ into
the cytoplasm of arterial smooth muscle cells. As mentioned earlier, higher intracellular Ca2+
concentrations increase the tone and contractility of vascular muscle tissue; thus calcium channel blockers
act to reverse that effect. Angiotensin-converting enzyme (ACE) inhibitors interfere with the renin-
angiotensin-aldosterone system by inhibiting the enzyme dipeptidase A, or angiotensin converting
enzyme, which is responsible for hydrolyzing angiotensin I to angiotensin II. However, ACE inhibitors
also stimulate the kallikrein-kinin system by inactivating the vasodilator bradykinin, blunting the blood-
pressure lowering effect. Angiotensin II receptor blockers are more selective at interfering with the renin-
angiotensin-aldosterone system because they do not interact with bradykinin.32
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Table 2: Classes of antihypertensive therapy and
Class of drug Compelling indications
Diuretics Heart failure,: isolated systolic
hypertension
3-Blockers Myocardial infarction
Calcium antagonists
ACE inhibitors
a-Blockers
Isolated systolic hypertension
Diabetes mellitus with proteinuria;
heart failure; myocardial
infarction
factors affecting suitability for patients33
Favourable effects on Adverse effects on co-morbid
co-morbid conditions conditions
Osteoporosis Gout; dyslipidaemia (high-dose
diuretics)
Angina; essential tremor Asthma; peripheral vascular
disease; depression; secondary
or tertiary heart block
Angina: diabetes mellitu.s Secondary or tertiary heart block
with proteinuria
Renal insufficiency Pregnancy; renovascular disease;
hyperkalaemia
Dyslipidaenuia prostatic Orthostatic hypotension
hypertrophy: glucose
intolerance
AngTotensin receptor ACE inhubitor-induced Pregnancy; renovascular disease;
blockers cough hyperkalaemia
ACE, angiotensin-converting enzyme.
After NHLBI released the JNC IV report in 1988, academic researchers began a series of three to
five year studies to gauge the effects of diuretics as initial therapy and to compare diuretics to beta
blockers. The results indicated that these treatments reduced cerebrovascular and cardiovascular
morbidity and mortality. 34 It is interesting to note that these trials represent one of the first instances of
employing a biomarker - reduction in blood pressure associated with antihypertensive treatment - as a
surrogate endpoint for morbidity and mortality in clinical trials. Use of this biomarker was to some extent
evidence-based: a meta-analysis of 12 antihypertensive clinical trials conducted before 1993 found that
patients in the trials who received antihypertensive therapy experienced a 52 percent reduction in the
occurrence of congestive heart failure compared to control or placebo subjects. Most of these trials used
diuretics as initial therapy.35
On the basis of these findings, in its 1993 JNC V report, the JNC revised its recommendations
suggesting that diuretics and beta blockers be the preferred initial treatment for hypertension, with
calcium channel blockers, ACE inhibitors, alpha blockers, and alpha/beta blockers as possible alternative
therapies, depending on the specifics of the patient's condition. The JNC V report upheld the view that
combination therapy (at lower doses of each individual drug) could effectively lower blood pressure with
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fewer side effects to the patient, but did not explicitly list recommended combinations. Rather, the JNC V
report merely outlined multiple dosage forms of several individual agents. 36
The JNC VI report, published in 1997, went much further than its previous two versions in
providing a clinical rationale for selecting particular antihypertensive therapies. In addition to explicitly
recommending that treatment decisions be based on systolic blood pressure, the report provided
evidence for the benefits of diuretics and beta blockers - as well as calcium antagonists - for elderly
patients with isolated systolic hypertension, and provided additional data showing a beneficial impact on
congestive heart failure and systolic dysfunction. One study cited by the JNC VI report demonstrated the
superiority of losartan potassium, a competitive antagonist of angiotensin II, over captopril, an ACE
inhibitor, in terms of decrease in total deaths.37 Another study indicated that a combined alpha/beta
blocker, carvedilol, reduced morbidity and mortality in patients with congestive heart failure, especially
in those with an ischemic basis.38 A third study showed that adding dihydropyridine calcium antagonists
to a regimen of diuretics and ACE inhibitors had beneficial effects on patients with heart failure.39, 40
JNC VI also provided more detailed information on the relative effects of certain classes of
antihypertensives on patient populations with renal dysfunction. Until this report, the JNC had not been
able to point to randomized, prospective, controlled clinical trial evidence to support recommendations
on the relative advantages of certain classes of antihypertensives in subsets of hypertensive patients.41
The report contained data indicating that ACE inhibitors were more beneficial than other agents for
patients with type I and II diabetes mellitus and nondiabetic chronic renal failure, and that calcium
antagonists also had renoprotective effects. 42
Lastly, the JNC VI report recommended a more flexible treatment approach than either JNC IV or
V. The JNC IV committee had advised physicians to take a stepped-care approach, adding other
antihypertensive agents only if the patient did not respond to first-line therapy. JNC V elaborated on this
theme, but maintained that diuretics and beta blockers should constitute the preferred method of
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treatment. In the JNC VI report, however, the committee gave physicians greater leeway in devising
individualized therapies, depending on a patient's comorbid conditions and special considerations. While
still adhering to the established first line of defense - diuretics and beta blockers - the JNC VI report
recognized that other classes of antihypertensives have greater benefits for patients with conditions such
as diabetes mellitus and chronic renal insufficiency. 43 In part, this could reflect the fact that a wider and
expanded set of patients were now being treated for hypertension.
2.5 JNC VI to JNC VII
One of the more noticeable amendments to treatment guidelines introduced in the 2003 JNC VII
report, issued six years after JNC VI, is the inclusion of the new classification of a condition called
"prehypertension" to describe adults with blood pressure ranging from 120 to 139 mm Hg systolic and/or
80 to 89 mm Hg diastolic. Previous reports had referred to "high-normal" blood pressure to describe the
range 130 to 139 mm Hg systolic and 85 to 89 mm Hg diastolic (JNC III through VI), but the JNC VII
brought out the new term in an attempt to focus physician's attention on these patients. (For a more
thorough treatment of historical classification schemes for hypertension, please see Appendix I). While
the committee did not recommend that these patients be prescribed antihypertensive drugs -
maintaining a healthy lifestyle is described in the JNC VII report as the recommended treatment - the
idea was to identify potentially hypertensive patients who might benefit from early intervention and to
encourage physicians to be vigilant in monitoring these patients' blood pressure.
An additional change from JNC VI involved simplifying the classification of the various stages of
hypertension. In the JNC VII report, NHLBI consolidated three stages of hypertension into two, grouping
patients with systolic blood pressure above 160 mm Hg and diastolic blood pressure above 100 mm Hg
with more severely hypertensive patients (2179/110 mm Hg), as shown in Table 3. In previous reports, the
committee had not explicitly stated that physicians should consider combination therapy for patients
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with stage 2 hypertension (2 160/100 mm Hg); many providers considered these patients well-treated
with just one antihypertensive agent.44
Table 3: Changes in Blood Pressure Classification, JNC VI to JNC VII 45, 46
jIN 6 CATEGORY
OPTIMAL
NORMAL
BORDERLINE
HYPERTENSION
STAGE I
STAGE 2
STAGE 3
<120/80
120-129/8o-.84
130-139/85-89
>140/90
140--159/90-99
160-179/1oo-109
2180/o10
JNC7 CATEGORY
NORMALS PREHYPERTENSION
WIC I HYPERTENSION
SsIAE IJ - SRGE 2
As to specific recommendations for antihypertensive drug treatments, the JNC VII report
remained conservative in the face of pressure to confirm that newer classes of compounds were superior
to diuretics (more recently approved classes of antihypertensives were thought to have blood pressure
independent benefits for patients at risk of cardiovascular disease). An unexpected finding occurred in
more recent trials, such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT). Results from this study showed that ACE inhibitors did not significantly reduce the risk
of congestive heart failure when compared to diuretics. The general conclusion reached by the committee
in the JNC VII report was that reducing cardiovascular morbidity and mortality rates is dependent on
reducing blood pressure, and that most of the differences between drugs reported in the superiority trials
reviewed by the JNC were in secondary endpoints, according to one analysis of the report.47 Potential
side effects represent one secondary basis for comparing the various classes of antihypertensive drugs;
these are shown in Table 4.
Table 4: Common Side Effects of Antihypertensive Therapy Classes
Class of Antihypertensive More common side effects Less common side effects
Diuretics (loop)48 dizziness or lightheadedness dryness of mouth; increased
when getting up from a seated thirst; irregular heartbeat;
position; blurred vision
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Diuretics (aldosterone receptor none abnormal vaginal bleeding;
blockers) 49  breast pain; chills; cloudy urine
Beta blockers s°  decreased sexual ability; breathing difficulty and/or
dizziness or lightheadedness; wheezing; cold hands and feet;
drowsiness (slight); trouble in mental depression; anxiety
sleeping and/or nervousness; constipation
Calcium channel inhibitors51  drowsiness (flunarizine only); breathing difficulty, coughing, or
increased appetite and/or weight wheezing; irregular or pounding
gain (flunarizine only) heartbeat; constipation; diarrhea
ACE inhibitors 52  coughing (dry, continuing) dizziness, lightheadedness, or
fainting; skin rash, with or
without itching, fever, or joint
pain; diarrhea; headache;
angiotensin II receptor none angioedema (rare)
antagonists 53
Indeed, the ALLHAT study was particularly controversial in that it was unable to conclusively
differentiate among a diuretic (chlorthalidone), a calcium-channel blocker (amlodipine), and an ACE
inhibitor (lisinopril) on the basis of the primary end point of the study: risk of fatal coronary heart disease
and nonfatal myocardial infarction. Nonetheless, the study authors (many of whom were also members
of the JNC VII committee) concluded that diuretics were a preferred first line of defense for treating
hypertension, because the ALLHAT results showed that amlodipine is less effective at preventing
congestive heart failure, and that lisinopril is inferior to amlodipine and chlorthalidone in reducing
patients' risk of stroke. Following the publication of the ALLHAT results, a debate ensued in the medical
literature questioning the strength of the evidence supporting the superiority of diuretics, and some
authors questioned whether cost (diuretics were long off-patent and therefore less costly than ACE
inhibitors and calcium channel blockers) had played a role in determining that diuretics should be the
first option for hypertensive patients. 54
The JNC VII report also provided additional guidance on which classes of antihypertensive drugs
were tied directly to reductions in mortality. Evidence showed that at least five classes of drugs reduced
mortality - thiazide and thiazide-type diuretics, ACE inhibitors, angiotensin receptor blockers, P-
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blockers, and calcium antagonists (both dihydropyridine and non-dihydropyridine) - a-blockers were
noticeably absent from this list. Lastly, the report concluded that combination therapy (two to three
drugs) was found necessary to reduce blood pressure in most patients to optimal levels, and provided
guidelines to physicians for selecting the right combination given a patient's risk factors and
comorbidities.55
2.6 Hypertension in African-Americans
High blood pressure occurs more often in African-Americans - 32 percent of blacks compared
with 23 percent of whites and 23 percent in Mexican Americans.5 6 In recent years evidence from clinical
trials has suggested that black patients may respond differently to certain antihypertensive and heart
failure treatments than other ethnic groups. The ALLHAT study in particular drew attention to the
potential differences between self-identified black and nonblack patients in their response to diuretics
and ACE inhibitors. Black patients who were randomized to ACE inhibitors had an increase of 5 mm Hg
(systolic) and 2 mm Hg (diastolic) in average follow-up blood pressure, 40 percent higher risk of stroke,
30 percent higher risk of heart failure, 15 percent higher risk of combined coronary heart disease, and 19
percent higher risk of combined cardiovascular disease versus black patients randomized to receive the
diuretic.57 Although these differences were statistically significant, it is a matter of debate how much
weight should be given these results when making recommendations for treating hypertension. For
example, despite the greater sensitivity to diuretic versus ACE inhibitor therapy in black patients, the
ALLHAT investigators concluded that physicians should prescribe diuretics as initial therapy
irrespective of the patient's race. In other words, ACE inhibitors were considered secondary
antihypertensive therapy for blacks, but also for whites, who did not show the same degree of sensitivity
in their response to diuretics and ACE inhibitors.
The debate over the significance of putative differences in response to treatment across ethnic
groups also has ramifications for clinical trial design. In practice, a properly designed clinical trial seeks
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to strike a balance between the need to conduct a sufficiently rigorous test of efficacy (which would
benefit from recruiting a narrowly-defined group of patients most likely to benefit from treatment) and
the need to determine the generalizability of the therapy to routine medical practice (which would benefit
from enrolling a broad range of patients). Thus, assessing the clinical benefits of a therapy targeting
patients of a specific ethnic group can be challenging.
In the case of the vasodilator BiDil, for example, academic and commercial researchers wanted to
show that the drug was effective in black patients, despite a lack of conclusive efficacy in a general trial
that included patients from a broad range of ethnic groups. The African-American Heart Failure Trial (A-
HeFT), the first heart failure trial in a self-identified all-black cohort, found that adding a fixed-dose
combination of isosorbide dinitrate/hydralazine (BiDil) to standard neurohormonal blockade (treatment
with a-blockers or 3-blockers) gave patients a 43 percent improvement in survival, a 33 percent reduction
in hospitalizations for heart failure, and a significant improvement in quality of life.58
Chapter 3: Clinical Trials
3.1 Attributes of Phase I-III Clinical Trials
Generally, a clinical trial is a planned experiment using human subjects designed to investigate
the safety and efficacy of a course of treatment for patients with a given medical condition. One defining
attribute of a clinical trial is that it relies on a limited sample of patients to make inferences about how to
treat future patients with the medical condition in the general population. In other words, a clinical trial
is designed to be prospective--to study how the patient sample will respond under the experimental
design and protocol. In contrast, a retrospective study, which examines the outcomes of patients treated
in a number of ways in the past, would not fall under the definition of a clinical trial. Retrospective
surveys are far less powerful in determining the safety and efficacy of particular treatments, primarily
because "unplanned observational studies contain serious potential biases (e.g. more intensive treatments
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given to poorer prognosis patients may appear artificially inferior)..." as Pocock writes in Clinical Trials:
A Practical Approach.5 9
As shown in Figure 3, clinical trials are often subdivided by phase of drug development. The
focus of a phase I clinical trial is typically the safety, rather than efficacy, of the drug in human subjects.
In pre-clinical studies, the pharmaceutical sponsor is likely to have tested the safety and non-toxic does of
the drug compound in a mammalian system--most often mice or rats. Phase I clinical trials represent the
first occasion the drug is tested in humans, or "first in man," to use industry parlance. In the past, healthy
volunteers for phase I trials were often recruited from the prison population; today phase I volunteers are
more likely to be graduate students enticed by the prospect of receiving a small fee in return for
participating in the study.60 A phase I clinical trial is often a dose-escalation experiment, which
investigates the effect of giving participants increasing doses of the study drug according to a
predetermined schedule. Phase I trials can also involve studies of drug metabolism and bioavailability.
Overall, phase I studies typically require between 20 and 80 subjects and patients.61
Figure 3: Timeline and Components of New Drug Development62
Pre-Clinical Clinical Approval Market
Toxicology Phase I
Phase I
Safety Phase IIISafetya
NDADosing Safety
Efficacy EfficacY Market I Phase
IVSide Effects
40% 75% 48% 64% 90%
I to 5yrs to 11 yrs 0.5 to2yrs 11 to 14 yrs
Phase II clinical trials are also fairly small-scale experiments, but the purpose of these trials is
broader, tending to investigate efficacy as well as safety and dosing. Typically, phase II trials involve no
more than 100 to 200 unpaid volunteer patients with a defined medical condition, and require between
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six months to two years to complete. Note that Figure 3 also includes estimates for the probability a given
drug will successfully transition from one phase of the drug development process to the next.63
Phase III clinical trials, the primary subject of this thesis, are the most rigorous and extensive type
of scientific clinical investigation of a new drug treatment. These trials investigate the safety and efficacy
of a treatment in hundreds to several thousand patients with a specific medical condition, and can
include studies of alternative formulations and doses of the drug. On average, the phase III process of
drug evaluation lasts about four years, and an estimated 64 percent of drugs tested in phase III trials
successfully make the transition into NDAs (New Drug Applications) or BLAs (Biologic License
Applications). 64 The concept of a "pivotal" trial is also worth introducing here, as it refers to the phase III
trials that are most significant for determining whether the sponsor has demonstrated that the study drug
is safe and effective. Whether a phase III trial is pivotal is to some degree in the eye of the beholder; often
the sponsor and FDA officials will disagree as to which phase III trials are actually pivotal. In the context
of the research presented in this thesis, pivotal refers to which trials FDA officials have determined to be
most significant for evaluating the safety and efficacy of the treatment.
3.2 Principles of Phase III Clinical Trial Design
A principle of a properly designed phase III clinical trial is that the study should be comparative,
i.e. the response of a group of patients receiving the drug under investigation is compared to a group of
patients receiving a placebo or standard treatment. Specifically, for a clinical trial to have statistical
validity, the patients must be randomly assigned to each of the groups- or arms-of the trial. Thus, a
randomized controlled trial is necessary to obtain an unbiased evaluation of the new treatment's potential
value in the general population of patients. Properly designing a phase III clinical trial also requires that
the sponsor develop and document the study protocol, which defines the exact type of patient to be
included in the study, the treatments to be compared, and the methods for evaluating patients' response
to treatment (the trial endpoints). As Pocock writes, the experimental protocol must address questions of:
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1) size--"the trial must recruit enough patients to obtain a reasonably precise estimate of response on
each treatment; and 2) avoidance of bias--the selection, ancillary care and evaluation of patients should
not differ between treatments, so that the treatment comparison is not affected by factors unrelated to the
treatments themselves." 6
One element of trial design of particular relevance to the research presented in this thesis is the
process for selecting patients to participate in a phase III clinical trial. In addition to ensuring that there
are sufficient numbers of participants to create a study of sufficient statistical power, trial designers must
establish strict criteria for which patients should be enrolled in the study. Defining these criteria involves
balancing the need to assemble a sample population that may be identified as representative of a future
class of patients to whom the trial's findings may be applied, with the need to assemble a sample
population most likely to benefit from the new treatment under investigation (thereby more easily
establishing the efficacy of the drug). In practice, trial designers use inclusion/exclusion criteria to find the
range of patient characteristics most likely to straddle the middle ground between representativeness and
specificity. An example of inclusion/exclusion criteria for patients in a trial of chemotherapy for advanced
colorectal cancer as cited by Pocock is given in Appendix III.
Another attribute of clinical trial design to which the thesis refers extensively is the concept of
trial arms. Typically a phase III pivotal trial is designed to randomize patients into one of at least two
groups: those receiving the study drug and those receiving a placebo designed to appear
indistinguishable from the study drug. Such a study is known as a placebo controlled trial. However, a
placebo controlled trial need not only randomize patients into just two groups, or arms. If the trial is
designed to also investigate the effect of varying the dose of the study drug, patients could be
randomized into additional arms, with each arm receiving a different dose of the study drug.
Alternatively, the purpose of a clinical trial could be to investigate whether a new drug is as efficacious as
an existing drug. In this type of study, known as an active control trial, patients would be randomized
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into an arm receiving the existing drug-the "active" comparator-and one or more arms receiving the
study drug (or even an additional arm receiving a placebo). In a third type of trial--an equivalence trial--
patients are randomized into arms comparing a new and existing drug in an attempt to establish that the
new drug is neither worse than nor better than the existing therapy. This trial is most often employed
when a sponsor is attempting to demonstrate the equivalence of a generic drug to its branded
counterpart. 66
Chapter 4: Research Methodology
4.1 Description of FDA Action Package
In order to determine who might benefit best from a particular antihypertensive therapy,
someone - typically a pharmaceutical manufacturer - must develop the drug first. To gain FDA
approval, a sponsor must usually submit data from at least two randomized clinical trials establishing
safety and efficacy. These trials, which are often phase III trials, require on the order of hundreds of
patients, and, in the case of antihypertensives, at least a year to complete. The past 15 to 20 years has seen
sponsors face both regulatory and commercial challenges in designing trials and assembling the dossier
of safety and efficacy data analysis needed to submit a New Drug Application (NDA).
Examining archival FDA data has provided quantitative insights into how clinical development
for pharmaceuticals in general, and antihypertensives in particular, has changed over the past 15 years.
This preliminary research has also helped generate several hypotheses concerning the importance of key
factors in the changes observed over this time period. In this analysis I have focused on data from the
primary studies cited by FDA Medical Officers as the basis for approval by the FDA. The primary
documents for this quantitative assessment are the NDA reviews for new molecular entities with
approval dates from 1991-2002, corresponding to submission dates between 1988 and 2001.
An NDA is divided into a number of different sections: non-clinical studies, including
pharmacology, chemistry, and microbiology; clinical studies; integrated summaries of efficacy and safety;
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labeling information; manufacturing details; and packaging information. For my purposes, the clinical
data section, comprised of the Medical Officer's Review, the Statistical Review, and the Clinical
Pharmacology Review, contained the most relevant data.
The primary data source, the Medical Officer's Review, is a comprehensive evaluation and
assessment of safety and efficacy, with emphasis on what the FDA interprets as pivotal phase III trials
(these may or may not be the same as those identified by the sponsor as pivotal). Secondary data sources,
such as the Statistical Review and the Clinical Pharmacology Review, were useful for finding summaries
of trial sizes and study design, as well as for information regarding special population and drug-drug
interaction studies. Table 5, shown below, is a condensed version of the data collection sheet I used to
assemble the information on each antihypertensive NDA relevant to my analysis of complexity.
Table 5: Information Captured from FDA Archives on Antihypertensives
NDA SUMMARY PIVOTAL TRIAL SUMMARY
Drug Identification Study Design
1. NDA # 1. Study Name
2. Generic Name 2. Study Features
3. Brand Name
4. Sponsor Name
5. Therapeutic Class
General Reviewing Information Study Structure
1. FDA Reviewing Division 1. Comparator
2. # of Review Cycles 2. Dosages
3. Priority/Standard 3. Dose Frequency
4. Fast Track/Accelerated Subpart H 4. Dose Duration
5. First in Class (Y/N) 5. # of Patients Enrolled
6. Submission Date 6. # of Drop-Outs
7. Approval Date 7. Attrition (%)
Dosage Endpoints
1. Route of Administration 1. Primary
2. Dosage Form 2. Secondary
3. Dosage Strengths
4. Inpatient/Outpatient
Safety # of Total Patients in Pivotal Trials
1. Black Box Warning at Approval
2. Black Box Warning Ever
3. # of Patients in Safety Database
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The FDA NDA reviews are electronically available from a variety of sources: the Drugs@FDA
public website, CDER's Division File System (DFS), and through the FDA's Action Package archival
system. The Drugs@FDA website is publicly available, but a considerable amount of relevant
(proprietary) material is often redacted. Both the DFS database and the Action Package archival system
include non-public information. The Drugs@FDA and DFS databases contain links to reviews, approval
letters, and labeling information. However, some information is unavailable, including data on non-
approved indications (only approved NDA indications are in the databases) and drugs that have
subsequently been withdrawn from the marketplace.
Because the FDA electronic archival process began in the 1980s, the Action Package is the most
useful data source for accessing a complete NDA. The Action Package, in its electronic form, is a set of
PDF files containing scanned-in documents of FDA reviews, notes to the file, and memos of meetings. As
shown in Table 6, the sample of antihypertensives approved between 1991 and 2002 is relatively
comprehensive. Although there are some inconsistencies in data reporting across the 16 antihypertensive
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Study Summary
1. Indications
a. Applied
b. Approved
2. Special Studies
a. Elderly (>65 yrs)
b. Pediatric
c. Cardiac
d. Liver Insufficiency
e. Renal Insufficiency
3. # of Pivotal Trials
a. According to sponsor
b. According to FDA
4. Total Studies in NDA
5. # of Drug/Drug Interaction Studies
Post-Marketing Commitments
1. Safety
2. Clinical
3. Pediatric
4. Special Population Studies
NDAs, the relative completeness of the sample provides confidence that the observations likely reflect
general trends.
Table 6: Antihypertensives submitted between 1988-2001
Compound Year of Year of Class of Antihypertensive Number of
Name Submission Approval Indications
Approved
1 felodipine 1988 1991 Ca channel 1
2 torsemide 1991 1993 diuretic (loop) 2
3 perindopril 1991 1993 ACE inhibitor 1
4 spirapril 1991 1994 ACE inhibitor 1
5 moexipril 1992 1995 ACE inhibitor 1
6 carvedilol 1993 1995 beta blocker 1
7 nisoldipine 1993 1995 Ca channel 1
8 losartan 1993 1995 angio II recep 1
9 trandolapril 1994 1996 ACE inhibitor 1
10 valsartan 1995 1996 angio II recep 1
11 irbesartan 1996 1997 angio II recep 1
12 eprosartan 1996 1997 angio II recep 1
13 candesartan 1997 1998 angio II recep 1
14 telmisartan 1997 1998 angio II recep 1
15 olmesartan 2000 2002 angio II recep 1
16 eplerenone 2001 2002 diuretic (aldosterone 1
receptor blocker)
4.2 Hypotheses
Before beginning the data collection and analysis, I constructed a set of hypotheses, built around
the central question of whether clinical trials for all drug classes in the investigation have become more
complex. For the purposes of antihypertensive NDAs, the relevant hypothesis is: 1) Clinical studies have
become more complex, according to the order in which a drug in a class is submitted for approval.
In the context of this thesis, it is important to note that "complexity"t refers to characteristics of
clinical trials for which I could obtain quantitative information and comparisons.
Chapter 5: Results and Discussion
t According to Merriam-Webster's Unabridged Online Dictionary, "complex," definition 2 a: having many varied
interrelated parts, patterns, or elements and consequently hard to understand fully <a complex camera with many
attachments> <a complex industrial process> <complex tissue>
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5.1 Summary of the Data
As an initial analytical exercise, I grouped the data by subclass of antihypertensive to determine
the average values associated with each of the variables important to this study. As shown below in Table
7, given the absence of any obvious trends, after viewing the data through this perspective I concluded
that subclass of antihypertensive therapy may not be the best way to explain the variation among the
putative indicators for clinical trial complexity.
Table 7: Summary of NDA Data, Arranged by Average for each Drug Subclass, Except Beta Blockers
diuretics calcium channel ACE angiotensin II receptor
blockers inhibitors antagonists
pivotal trial patients per 806.5 1690.5 884.7 1929.6
approved indications
average # of patients per 276.6 258.2 243.1 382.1
pivotal trial
average # pivotal trials 6.5 6.5 3.7 5.0
per NDA
average # of arms per 4.3 4.0 4.9 4.6
pivotal trial
average # of drug-drug 7.0 6.0 4.0 7.1
interaction studies per
NDA
average % patient drop 6.8% 12.7% 15.3% 10.6%
outs from pivotal trials
average dose duration 73.2 46.5 70.6 58.2
(in days)
average # of days to 604.5 959.0 781.0 445.7
approval
While some subclasses of antihypertensives are generally older than others, submission dates for
the subclasses of calcium channel blockers and diuretics span five and ten years, respectively, and are
interspersed with NDA submissions of drugs in other subclasses, as was indicated in Table 6. Thus, it is
possible that viewing the data in chronological order of NDA submission date may offer a more
informative analytical framework than examining by subclass.
In the sections that follow I attempt to follow this approach. I begin with a discussion of the
number of patients associated with the efficacy and safety databases, and investigate the number of
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pivotal trials per NDA and the number of study arms in these pivotal trials. Variation in the number of
drug-drug interaction studies offers another probe of clinical trial complexity; percentage of patient
dropouts provides a glimpse into the relative importance of discontinuations in complicating clinical trial
design. Data on time to approval offer some validation that FDA efforts to reduce review time have met
with success. Lastly, differences in inclusion/exclusion criteria over time present additional insights into
how clinical trial design has changed.
It is worth noting there are many possible metrics for clinical trial complexity for which I do not
observe trends (data not shown). For example, by inspection I can determine that there was no trend over
time for dose duration, defined as the number of days patients in the trial were given the active
compound. Likewise, I do not observe any trend in the prevalence of combination, crossover, or
multidose trials in antihypertensive NDAs over time. Combination trials, defined as clinical studies to
investigate the combined antihypertensive effect of the study drug plus another therapy (usually the
diuretic hydrochlorothiazide), appear primarily in supplementary NDAs, and only occasionally did I
observe these trials in my sample of antihypertensive NDAs. Nor are there trends associated with the
number of clinical trials deemed "pivotal" by the sponsor, even when this number is normalized by the
number of pivotal trials deemed pivotal by the FDA.
5.2 Increase in Patients per Pivotal Trial
A broad look at how the complexity of antihypertensive NDAs has changed with time can be
obtained from examining the average number of patients per FDA pivotal trial as a function of
submission date. Pivotal trial is a somewhat ambiguous term, given that the drug sponsor and FDA often
differ in their determination of which trials are necessary to support the application. In this analysis I
define pivotal trials as the set of studies that FDA reviewers deemed necessary and sufficient to support
the drug's efficacy (pivotal trials were necessary but not sufficient to support a drug's safety, the latter
entailing analysis of the entire safety database). For some NDAs, the Medical Review listed the trials that
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FDA considered vital to supporting the application; in others, it was necessary to seek additional
guidance and/or confirmation of the number of pivotal trials from the Statistical Review, which tended to
elaborate on the validity of the trials under review.
It should be noted that there is no obvious trend associated with the total number of patients in a
particular NDA per approved indication, but when the total is normalized by the number of trials
deemed pivotal by FDA, the upward trend is visible, as shown below in Figure 4 (Note: individual data
points have been removed because of FDA policy restricting the release of proprietary data). In a simple
bivariate regression, the coefficient estimate on the explanatory variable of submission datet is positive
and significant (R2 = 0.513, t statistic = 3.70, p-value = 0.003). Between 1987 and 2001, the predicted number
of patients per pivotal trial more than doubled, from about 200 to 450, an average annual growth rate of
about 6.0 percent. Identifying the exact reasons underlying the increase in patients per trial is challenging,
Figure 4: Average Number of Patients per FDA Pivotal Trial
Average Number of Patients per FDA Pivotal Trial
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however, as there could be several explanations for this phenomenon. For example, the effect of the drug
on blood pressure could be small, requiring a greater sample size to establish the validity of the drug's
f Microsoft Excel stores dates as sequential numbers which are called serial values. By default, January 1, 1900 is
serial number 1, and January 1, 2008 is serial number 39448 because it is 39,447 days after January 1, 1900. To
normalize the data, I set the first NDA submission date, February 26, 1988, equal to zero, and adjusted the other
submission date values accordingly. The normalization allows me to present a more meaningful y-intercept value.
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effectiveness (minimum effect size). Alternatively, a larger patient population may have been necessary
due to changes in FDA guidelines for clinical trials, reflecting safety concerns. Another scenario could
involve the sponsor adding comparator arms for commercial reasons, thereby requiring a greater number
of patients to reach a statistically significant conclusion.
In an attempt to understand these complications, I generalized the linear least squares regression
analysis to allow for differential relationships among NDAs in different drug classes. Because there are
five classes of antihypertensive drugs embedded in the sample - diuretics, beta blockers, calcium
channel blockers, ACE inhibitors, and angiotensin II receptor antagonists - I incorporated four dummy
variables into the regression to explore any differential aspects involving the various drug classes.
Specifically, I estimated a multivariate regression in which in addition to the submission date I added
four class dummy variables, with the angiotensin II receptor antagonist class acting as the reference
intercept term and the coefficients on the four dummy variables representing differential intercepts from
the reference class. The results indicated that there were no significant differences among the five drug
classes.§ Repeating the analysis with three dummy variables allowed me to combine beta blockers (n = 1)
and diuretics (n = 2) into a single class, but again the regression results did not point to significant
differential contributions from any of the four aggregated classes of antihypertensive drugs.**
There is, however, some very weak evidence that the increase in average number of patients per
pivotal trial reflects a greater investment on the part of sponsors in establishing drug safety and efficacy.
With respect to the antihypertensive NDAs for which safety database information was available (n = 12),
the average size of the safety database also increased with submission date, when normalized by the
number of trials deemed pivotal by the FDA, as shown in Figure 5 (R2 = 0.163, t statistic = 1.396, p-value =
§ While the value for R2 increased to 0.688 as a result of incorporating the four dummy variables, none of the t
statistics for the dummy variables had an absolute value greater than 1.771. The lowest p-value for the dummy
variables was 0.110.
** Again, while the value for R2 increased to 0.613 (from 0.513), the greatest absolute value associated with the t
statistics for the dummy variables was 1.334, and the lowest p-value was 0.212.
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0.193). Again, individual data points have been removed in order to comply with FDA policy on
nondisclosure of proprietary data. Note that this trend is positive but not statistically significant, perhaps
due partly to the further reduced sample size (only 12 out of the available 15 NDAs had reliable data on
safety database size). Notably, however, over the eleven year period between 1990 and 2001, the
estimated regression line predicts an approximate doubling in size of safety database per FDA pivotal
trial, from slightly more than 600 in 1990 to about 1,200 in 2001, an average annual growth rate of 6.5
percent. Although discussion of efficacy and safety are beyond the scope of this report, it is conceivable
that greater numbers of patients are required when the therapeutic has marginal benefit in terms of safety
and efficacy.
Figure 5: Size of Safety Database per FDA Pivotal Trial
Size of Safety Database Per FDA Pivotal Trial
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5.3 Trends in Number of Pivotal Trials per NDA
Moving beyond the sheer number of patients involved in establishing efficacy and safety, I
examined how the number of pivotal trials per NDA varied over time. As a first pass, I looked at all the
hypertensives in the sample, and plotted the number of pivotal trials per NDA by submission date. I
estimated a simple bivariate regression equation with the number of clinical trials as the dependent
variable, and the NDA submission date as the explanatory variable. The result is shown in Figure 6.
Given the variation in the data, there is fairly little in the way of a trend, but what trend does exist
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Figure 6: Number of FDA Pivotal Trials per NDA
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appears to show that the absolute number of pivotal trials per NDA has tended only modestly to decline
over time, but not statistically significantly (R2 = 0.1778, t statistic = -1.677, p-value = 0.118).tt The
predicted number of FDA pivotal trials per NDA is about 3.5 in 2001, whereas in 1987 it is considerably
larger at about 7.0.
5.4 Trends in Number of Arms per Pivotal Trial
To help explain some of the trends described earlier, particularly the increase in average number
of patients per pivotal trial, I investigated trends in the number of arms per pivotal trial. Data abstracted
from the antihypertensive NDAs allows me to calculate an average number of arms per trial specified in
each NDA.
Generally, an arm of a trial is any discrete group of patients randomized at the beginning of the
study to undergo treatment different from the other randomized groups. Thus, a group of patients who
received the study drug plus a diuretic would be an arm separate from a group of patients just receiving
the study drug. Likewise, a group of patients randomized to receive 15 mg of the study drug per day
over the course of an eight week study would be a different arm from a separate group of patients
tt- I also estimated a bivariate regression equation for which the dependent variable was the ratio of pivotal to total
number of clinical trials, (where total trials are defined to be the total number of clinical studies referenced in the
NDA), with submission date as the explanatory variable. Although the coefficient estimate on submission date was
positive, it was not significant (p-value = 0.364, R2 = 0.064).
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randomized to receive 25 mg per day of the study drug over the course of the clinical trial. On the other
hand, a group participating in a titration study, which received one dose for a given number of weeks,
and then a higher dose for following weeks, would be considered part of the same arm in the trial. Given
this classification, I estimated a simple bivariate regression equation with average number of arms per
pivotal trial as the dependent variable, and submission date as the explanatory variable. The results
provide qualified support for an increase in complexity over time, as shown in Figure 7 (R2 = 0.340, t
statistic = 2.588, p-value = 0.022). The estimated regression line implies that while the average number of
arms per FDA pivotal trial was about 3.3 in 1987, by 2001 it had increased to about 5.5, an approximately
67 percent increase.
Figure 7: Average Number of Arms per NDA by Submission Date
In order to ascribe this trend to greater complexity in clinical trial design with greater reliability,
it is necessary to probe more deeply into the data. Regression analysis using dummy variables to
represent the various classes of antihypertensives provides one avenue. Using a procedure identical to
that described above for the number of patients per pivotal trial, I defined three dummy variables to
classify the data on arms per trial according to: 1) diuretics + beta blockers; 2) calcium channel blockers;
and 3) ACE inhibitors, with angiotensin II receptor antagonists as the reference class. The equation for the
regression that results is given by:
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where:
xl is the explanatory variable for submission date;
x2 is the dummy variable for diuretics and beta blockers;
x3 is the dummy variable for calcium channel blockers;
x4 is the dummy variable for ACE inhibitors;
and the reference class consists of angiotensin II receptor antagonists.
The results indicate that the dummy variable for ACE inhibitors came closest to displaying a differential
intercept relative to the reference class of angiotensin II receptor antagonists (R2 = 0.605, coefficient = 1.358,
t statistic = 2.253, p-value = 0.048).$$ Notably, in comparison to the simple bivariate regression, the
coefficient estimate on xi (submission date) increased in this specification with differential intercepts, and
became more significant (R2 = 0.605, coefficient = 0.0007, t statistic = 3.544, p-value = 0.005).
Delving a little deeper into the data, I also identified the number of arms in each NDA devoted to
comparators and combination therapy, rather than a placebo. Collecting this information was designed to
help gauge how closely the number of arms in an NDA is tied to variations in dosing regimens, or to
comparisons with competing drugs and combination therapy. In several NDAs the sponsor designed
combination trials to gauge the relative antihypertensive effect of the study drug alone, versus the study
drug taken in combination with the diuretic hydrochlorothiazide. (However, to gain FDA approval for
the marketing of the study drug plus hydrochlorothiazide, the sponsor was required to submit a
supplemental NDA). Total arms were then defined as the aggregate number of arms associated with the
set of pivotal trials.
#$ I also performed this analysis using four dummy variables to classify the data according to diuretics, beta blockers,
calcium channel blockers, and ACE inhibitors, with angiotensin II receptor antagonists as the reference class. The
analysis produced similar if slightly less significant results, showing that ACE inhibitors were best able to display a
differential intercept relative to the reference class of angiotensin II receptor antagonists (R2 = 0.609, coefficient = 1.382,
t statistic = 2.167, p-value = 0.058). However, because there are only two diuretics and one beta blocker in our study, I
thought it best to group diuretics and beta blockers, limiting the regression to three dummy variables.
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While one could hypothesize that comparator arms might be more prevalent for follow-on drugs
within a specific class, the data show otherwise. For example, the NDA submitted second in one
antihypertensive subclass contained a total of seven comparator arms, compared with zero in the NDAs
for the two members of that subclass submitted before and afterwards. Likewise, there does not appear to
be any chronological significance to the prevalence of comparator arms for the angiotensin II receptor
antagonists contained in the sample. NDAs corresponding to three members of a different
antihypertensive subclass contained no comparator arms, whereas the first two from the class to be
submitted contained three and five comparator arms, respectively. One possible interpretation is that
complexity is greater for the first two entrants, because later entrants have learned from the predecessor
compounds "what to do and not to do" in their development programs.
5.5 Increase in Drug-Drug Interaction Studies over Time
To determine whether an investigational new drug has the potential to interfere with the body's
ability to metabolize or excrete other drugs that a patient may be taking concurrently, often the FDA
requires that sponsors undertake drug-drug interaction studies. Of particular concern are drugs that
either promote or interfere with the ability of cytochrome P450 enzymes (and N-acetyl and glucuronosyl
transferases) in the liver to eliminate another active compound present in the patient's bloodstream. 67 For
the antihypertensive drugs I studied, a typical drug-drug interaction study investigated the possibility of
adverse drug reactions in patients receiving the study drug and another commonly prescribed
medication such as digoxin, a treatment for congestive heart failure. 68
With the data abstracted from the antihypertensive NDAs, I investigated how the prevalence of
drug-drug interaction studies has changed over time. I estimated a bivariate regression equation with the
number of drug-drug interaction studies as the dependent variable, and the submission date as the
explanatory variable. As shown in Figure 8, the number of these studies per NDA trended upward over
the 14 years under investigation, implying that sponsors were increasingly designing clinical trials to
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provide evidence regarding possible adverse drug-drug interactions (R2 = 0.322, t statistic = 2.484, p-value =
0.027). The estimated regression line implies that while the number of drug-drug interaction studies per
approved NDA was about 4.0 in 1987, by 2001 this more than doubled to 8.5, an average annual growth
rate of 5.5 percent.
Figure 8: Number of Drug-Drug Interaction Studies
Part of this increase could be due to increased awareness and understanding of the mechanisms
through which a study drug can interact with other commonly prescribed medications. In the early 1990s
the histamine Hi-receptor antagonist terfenadine (Seldane) became well-known for drug interactions that
were uncovered only years after its initial approval in 1985. Because terfenadine was the first
antihistamine that did not cause drowsiness, sales grew to over $600 million in 1995,69 but the
accumulation of evidence of occurrence of torsade de pointes (a variant of ventricular tachycardia) with
drug-drug interactions involving terfenadine led to its withdrawal from the market in 1998. In fact, a
report in FDA Consumer magazine cites the withdrawal of terfenadine, along with the drug interaction
related withdrawals of the heart drug mibefradil (Posicor) in 1998, the antihistamine astemizole
(Hismanal) in 1999, and the heartburn drug cisapride (Propulsid) in 2000, as contributing to a substantial
increase in the number of drug-drug interaction studies submitted with NDAs to the FDA. 70 Notably, the
JNC VII report, released in 2003, discusses the effect of common prescription and illegal drugs on blood
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pressure, but does not specifically address the potential for drug-drug interactions. As there could be
many explanations for why characteristics of NDAs (under the supervision of FDA) and JNC
recommendations diverge, perhaps it is sufficient to say that the JNC recommendations placed a slightly
lesser emphasis on the intricacies of pharmacology.
Other factors may also play into the overall trend toward more drug-drug interaction studies. In
1997 and 1999, FDA issued guidance to industry related to drug interaction studies, which may have
encouraged sponsors to pay greater attention to these studies. The 1997 guidance document addressed
the use of in vitro studies to examine potential drug interaction problems at an early state in the drug
development process. Noting that advances in assay technology had made using human tissue and
recombinant enzymes for drug-drug interaction studies easier, the guidance document promoted in vitro
studies as an efficient means of uncovering adverse drug interactions that "often can reduce or eliminate
the need for further clinical investigations."7' In contrast, the 1999 guidance document suggests that
sponsors' drug-drug interaction studies "explore whether an investigational agent is likely to
significantly affect the metabolic elimination of drugs already in the marketplace and, conversely,
whether drugs in the marketplace are likely to affect the metabolic elimination of the investigational
drug."72 Thus, as the number of medications on the market has grown over time, sponsors have
encountered an increasingly significant burden to establish that the study drug does not adversely
interact with other treatments likely to be taken the patient population.
5.6 Trends in Patient Drop-out Rates
Comparing patient trial discontinuation, or drop-out rates, across the antihypertensive NDAs
presents another opportunity to assess empirically the hypothesis of increasing complexity. A general
heuristic of drug development is that sponsors often seek to develop a drug in an already established
class if the new compound has fewer or less onerous adverse side effects than drugs in that class already
on the market. Because adverse side effects are often the cause of patients dropping out of a clinical study,
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in theory it might be possible to track this phenomenon by examining the patient drop-out rate within a
class of antihypertensives over time. The results of this analysis are shown below, in Figure 9.
Figure 9: Patient Drop-out Rates per NDA by Submission Date
As is apparent, there is no statistically significant trend with submission date as the sole
explanatory variable (R2 = 0.0004, t statistic = -0.068, p-value = 0.947). Additional regression analyses with
dummy variables classifying for antihypertensive drug class indicated that none of these categories
helped to explain the variation in patient drop-out percentage (all t statistics and p-values for the dummy
intercept variables pointed toward insignificance). A separate analysis using one dummy variable
representing first in class drugs and time as explanatory variables also did not produce statistically
significant results.§ Lastly, I investigated whether a trend might emerge after dropping the first two data
points, which appear to be gross outliers. While a simple bivariate regression analysis again pointed
toward insignificance (R2 = 0.197, t statistic = -1.566, p-value = 0.148), the statistics do noticeably improve.
In a later section (Chapter 6) I qualitatively examine changes over time in patient
inclusion/exclusion criteria for pivotal clinical trials. One could imagine that changes in the stringency of
" With submission date and a dummy variable for first in class drugs as explanatory variables, the value for R2 in the
regression analysis of patient drop out rates increased to 0.02. For submission date, values for the t statistic and p-
value were -0.113 and 0.912, respectively; for the first in class dummy variable, values for the t statistic and p-value
were -0.471 and 0.647, respectively.
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inclusion/exclusion criteria might also have some bearing on patient drop-out rates. For example, if
inclusion/exclusion criteria were to become less selective over time, a greater percentage of the
participants in a clinical trial might be forced to drop out, for health or compliance reasons. As it turns
out, the evidence suggests that several inclusion/exclusion criteria have become marginally more
selective, such as screening out patients with greater than average body mass index or who recently
participated in another clinical trial (please see Chapter 6 for more detailed discussion). It is unclear
whether these more stringent criteria contributed to the variation in patient drop-out rates over time.
5.7 Decreasing Time to Approval
My analysis also found a marked trend with respect to the length of time required for FDA to
review and approve an NDA (the sample is limited to NDAs eventually receiving FDA approval). As
shown in Figure 10, the more recent the submission date, the more rapidly the FDA approved the NDA
(R2 = 0.678, coefficient = -0.171, t statistic = -5.237, p-value = 0.0002). The estimated regression line implies
that while NDA review times in 1987 were about 1050 days (35 months), by 2001 this had fallen to about
200 days (6.7 months), an average annual decline about 11.2 percent. While it is possible that FDA
Figure 10: Days to FDA Approval for each Antihypertensive NDA as Function of Submission Date
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reviewers were becoming more efficient at reviewing NDAs even while clinical trials were becoming
more complex, a more likely explanation for this trend lies with the passage of the Prescription Drug User
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Fee Act in 1992, which allowed FDA to boost its budget for NDA reviewers by charging sponsors fees
associated with the submission and review of the application, and hiring more reviewers.73,74
Chapter 6: Inclusion/Exclusion Criteria
Inclusion/exclusion criteria present another dimension to divine for trends with respect to NDA
submission date and among the antihypertensive drug subclasses. The characteristics of trial patient
populations are also potentially valuable as a means of probing the degree to which the trials reflect
actual point-of-care delivery of antihypertensive therapeutics and/or changing JNC treatment guidelines.
To investigate these potential relationships, I collected quantitative data on the inclusion/exclusion
criteria for 14 of the 16 antihypertensives. I then set up a spreadsheet to summarize the similarities and
differences in inclusion/exclusion criteria. Possible values for the fields were: 1) "yes" - the particular
criterion is used in a trial; 2) "no" - the criterion is not applied to the trial; 3) "unclear" - it could not be
determined from the NDA action package whether the trial applied the criterion; and 4) "n/a" - if the
trial in question was in support of an indication other than the treatment of hypertension.
It is noteworthy that the inclusion/exclusion criteria for the 14 antihypertensives do not show a
marked change in maximum or minimum diastolic blood pressure for inclusion in a study. The minimum
diastolic blood pressure varied between 90 and 95 mm Hg, and the maximum varied between 110 and
115 mm Hg, but there was no discernible trend with respect to time or chronologically within subclass of
antihypertensive therapy. Additionally, the blood pressure criteria were stated only in terms of diastolic
blood pressure, not systolic blood pressure, apparently in accordance with FDA guidance prior to 2000,
which recommended that sponsors rely on diastolic blood pressure as the basis for assessing the efficacy
of new antihypertensive therapies.75 (Previously, in 1997, the JNC VI report had recommended that all
treatment decisions be based on systolic blood pressure.) It is apparent, however, that additional
inclusion criteria were set within the angiotensin II receptor blockers to restrict for variations in blood
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pressure in patients, and to identify and exclude patients whose blood pressure fluctuated significantly
- a condition known as labile hypertension - during the placebo run-in period.
Two other observations emerge from this examination of inclusion/exclusion criteria. Within the
subclasses of diuretics (n = 2) and ACE inhibitors (n = 3) there is a clear trend toward including
restrictions on patients' weight in the more recently submitted NDAs. This criterion, expressed in terms
of body mass index (patients whose weight exceeded a given variation from their ideal based on height),
would presumably complicate the selection process as the percentage of obese Americans continues to
rise. A further observation involves racial criteria. While most of the studies did not place any restrictions
on the racial or ethnic make up of the patient population, there were three antihypertensive NDAs that
did. One of the pivotal trials for an antihypertensive restricted enrollment to no more than 25 percent
black patients, and another trial in the same NDA required that only non-black patients could enroll.
Likewise, one of the trials for a different antihypertensive was restricted to "Caucasians only," and a trial
for a third antihypertensive stipulated that study sites "were requested not to enroll more than 30 percent
blacks."
One inclusion/exclusion criterion involved a restriction on patients who participated in a study of
a different investigational drug in the 30 days prior to the antihypertensive trial. Within both the
subcategories of ACE inhibitors (n=3) and angiotensin II receptor blockers (n=7), only the more recently
filed NDAs contained this exclusion criterion. One might theorize that even while sponsors are increasing
the average number of patients per pivotal trial, they are simultaneously making a greater effort to be
selective to avoid contaminating the patient pool with those who have engaged in other studies of
investigational drugs.
It is worth noting that of all the 81 studies in the sample encompassing these 14 NDAs, only two
studies were not double-blinded. These two studies were included in NDAs submitted toward the
beginning of the range of submission dates in the sample.
-51 -
Chapter 7: Conclusion and Limitations
Although the number of NDAs examined in the antihypertensive class is too small to permit
rigorous statistical analyses, I am nonetheless able to observe a number of apparent trends within the set
of NDA submissions for antihypertensives approved by the FDA. Specific trends in the metrics I observe
include:
* Trial sizes increase over time as measured by patient enrollments per trial (p-value = 0.003);
* Clinical trial designs over time have included greater numbers of arms per trial (p-value = 0.022);
* The number of drug-drug interaction studies in antihypertensive NDAs has increased with time
(p-value = 0.027); and
* Inclusion/exclusion criteria for patients in trials have not changed greatly over time within
subclasses of antihypertensives with respect to maximum and minimum blood pressure, but
have tended to include greater restrictions over time on patient weight, as well as on the racial
makeup of patient populations (qualitative analysis).
A number of potential metrics for complexity do not exhibit any trends over time, or when
compared across the various subclasses of antihypertensive drugs. That said, however, increases in trial
size, in number of arms per trials, and in number of drug-drug interaction studies offer preliminary
support for the hypothesis that clinical trials associated with NDA applications for antihypertensives
have become more complex over the last two decades, perhaps contributing to the increasing cost of drug
development.
My analysis of the Medical Reviewers' summaries of 15 antihypertensives approved by the FDA
since 1991 has revealed a number of tentative findings. I emphasize these findings are tentative for at
least three reasons. First, the sample size of at most 15 is quite small, implying that it may be difficult to
generalize from the trends I observed. Second, complete data were unavailable for one of the 16
antihypertensives approved by the FDA since February 1991. Lastly, it is important to emphasize that a
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number of putative indicators of complexity did not exhibit any observable trends. The number of trials
deemed pivotal by the sponsor, for example, did not increase with time; nor did I observe any increase in
average dose duration for trials deemed pivotal by the FDA.
In spite of these limitations, I find that average trial sizes have increased over time as measured
by patient enrollments per trial. While there could be many reasons for the greater number of patients
associated with pivotal trials in antihypertensive NDAs over time, I conjecture that this may, at least in
part, be due to sponsors' more thorough efforts to establish safety and efficacy. I observed other trends
that support this supposition. Clinical trial designs over time have tended to include greater numbers of
arms per trial; furthermore, the number of drug-drug interaction studies in antihypertensive NDAs has
increased with time. Together these apparent trends offer preliminary support for the hypothesis that
clinical trials in support of NDA applications for antihypertensives have become more complex over the
last two decades.
Chapter 8: Policy Implications
8.1 FDA Guidance and JNC Treatment Recommendations
Given the lack of available information, it is impossible to know exactly what guidelines FDA
had in place between 1988 and 2000 with respect to clinical trials for antihypertensives. Yet it is clear that
JNC recommendations for the treatment of hypertension evolved over this time period. Should we be
concerned that changes in JNC recommendations for treatment did not map directly on to changes in the
inclusion/exclusion criteria for antihypertensive NDAs?
As one example, consider the 1997 JNC VI report's conclusions that systolic blood pressure (the
pressure that blood exerts on the artery walls as the heart contracts to pump out the blood) is a preferable
metric for hypertension treatment recommendations and goals than diastolic blood pressure (the
measurement of pressure as the heart relaxes to allow the blood to flow into the heart). One might expect
that given the JNC's conclusion, inclusion/exclusion criteria for trials submitted with NDAs after 1997
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would state the acceptable range of hypertension for patients to be enrolled in terms of systolic blood
pressure. Yet this is not the case. Instead, up to and including the last antihypertensive NDA, which was
submitted in 2001, all inclusion/exclusion criteria for the acceptable range of hypertension were stated in
terms of diastolic blood pressure. There just happens to be a simple explanation: according to literature
reports, FDA used diastolic blood pressure as the basis for its criteria in assessing the efficacy of new
antihypertensive medications.76
It is unclear whether FDA was right or wrong to use diastolic blood pressure to assess the
efficacy of new antihypertensive drugs. There would be no harm in relying on diastolic blood pressure if
an antihypertensive drug were equally effective at lowering diastolic and systolic blood pressure. The
March 2000 ICH guidance document states, "Although all drugs to date have reduced both systolic and
diastolic blood pressures, the recognition of isolated or predominant systolic hypertension as a significant
and remediable risk factor demands explicit evaluation of the effect of a drug on systolic blood
pressure."77 Without further research to show that antihypertensives submitted between 1988 and 2000
were less effective because the inclusion/exclusion criteria were stated in terms of diastolic blood pressure,
it appears that FDA's delay in updating its guidance was inconsequential.
Furthermore, from analyzing inclusion/exclusion criteria for the 15 antihypertensives submitted
between 1988 and 2001, there is evidence to suggest that the minimum diastolic blood pressure for
inclusion in a study did not stray from within JNC's definition of "mild hypertension," or what was later
referred to as "stage 1" hypertension (see Appendix I for more details). For all 15 antihypertensives, the
minimum diastolic pressure ranged between 90 mm Hg and 100 mm Hg, with the most common criterion
being 95 mm Hg. By comparison, under JNC III and JNC IV, "mild hypertension" in terms of diastolic
pressure was defined as 90-104 mm Hg, and under JNC V through JNC VII, "stage 1" hypertension
referred to diastolic pressures of 90-99 mm Hg. One could argue that FDA should have been more
vigilant in providing guidance directing sponsors to enroll patients with even the mildest form of
-54-
hypertension, as defined by the JNC. If FDA had done this, none of the observed inclusion/exclusion
criteria would have defined the minimum diastolic blood pressure above 90 mm Hg. On the other hand,
as all of the observed minimum criteria for diastolic blood pressure fall within the JNC's definitions for
"mild" or "stage 1" hypertension, it is unclear if reducing the minimum diastolic pressure by 5-10 mm Hg
would have been meaningful.
8.2 Is FDA Responsible for the Increasing Complexity of Clinical Trials?
My findings, though preliminary, suggest that important attributes of clinical trials for approved
antihypertensives submitted between 1988 and 2001 have become more complex over time. Yet it would
be desirable to relate the observed trends showing increasing complexity with data on the costs of clinical
trials. This would allow one to gauge whether and to what extent these developments have contributed
to the rising cost of drug development generally. Unfortunately, calculating the significance of such a
contribution to drug R&D costs would require detailed knowledge of the accounting used for clinical
trials. For example, I would need access to data on the marginal cost per patient in an average trial, and
the marginal cost per arm of a study--proprietary data difficult to acquire in the context of a Master's
thesis.
However, it may be appropriate to comment generally on some of the potential causes of the
trends towards increasing complexity I observed for several characteristics of antihypertensive clinical
trials. One question that has implications for regulatory policy is whether trials are becoming more
complicated because of FDA requirements--e.g. guidance that would push pharmaceutical sponsors
toward including more patients in pivotal clinical trials--or because of decisions the sponsors made
independently for commercial reasons.
If it were true that FDA guidance served as a forcing function for changes in the characteristics of
pivotal clinical trials, one could attempt to find confirmatory evidence by reviewing the FDA guidance
for antihypertensive clinical trials in effect during the time period under investigation in this thesis, and
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attempting to pick out how clinical trials may or may not have responded to changes in the underlying
guidance. But there are two problems with this approach. First, only one of the two guidance documents
in effect between 1988 and 2001 is available. The publicly-available guidance document, the most current
guidance related to antihypertensive clinical trials, is a draft consensus principle signed in March 2000 by
the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). The previous guidance document, entitled, "Clinical Evaluation
of Antihypertensive Drugs" and in effect from May 1988 until March 2000, is not available via the FDA
website or with the help of colleagues at the agency. The second problem with this approach is that only
two of the fifteen antihypertensive NDAs in the sample were submitted after March 2000. In other words,
even if the May 1988 document were available for review, it would be difficult to make a proper
comparison between clinical trials submitted under the May 1988 guidance and those submitted under
the March 2000 guidance.
It is possible that informal correspondence between FDA officials and representatives of the
pharmaceutical sponsor could have been a conduit for FDA advice ultimately responsible for the
observed increases in clinical trial complexity. Given the vague and general nature of the available FDA
guidance document relevant to clinical trials for antihypertensives, consultations between company
representatives and FDA officials--either over the phone, in writing, or in person--might be more
valuable in determining how much of an impact on trial design could be tied to FDA consultations. Again,
the problem is one of access to the necessary information. According to Dr. Frank Douglas, an advisor to
this thesis, a sponsor likely maintains records of these interactions, but it is unclear to what extent FDA
also records the details of every conversation with sponsors.
The other perspective on this issue is to attempt to find significant evidence of increasing
complexity, the cause of which under no circumstances could be ascribed to FDA dictates or advice. For
example, I conjectured that pharmaceutical sponsors seeking to market a drug within an already
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established subclass of antihypertensive might be motivated for commercial reasons to compare its drug
in clinical trials to the drugs of that subclass already on the market. If the clinical trial established that the
new drug had advantages over the currently marketed therapy, the company might have a tool with
which to differentiate its product and increase sales of its new drug. However, as described in Chapter 5,
I did not observe any trends showing increasing frequency of comparator arms within antihypertensive
subclasses over time.
Nonetheless, there are other explanations for the observations that would place responsibility for
the increases in complexity in the hands of pharmaceutical sponsors. Two of the three statistically
significant observations of increasing complexity-a trend toward more patients in pivotal trials over
time and a trend toward more arms per trial over time--are not necessarily independent phenomena. In
other words, an increase in the number of arms per pivotal trial over time might require that the overall
number of patients involved in pivotal trials also increase over time. As discussed above, I did not find
evidence that the number of arms per pivotal trial increased due to a tendency on the part of sponsors to
include comparisons with competitors' drugs. However, this leaves open the possibility that the increase
in arms per trial was instead due to greater emphasis on dosing comparisons in pivotal trials.
Why would sponsors tend to include more arms in pivotal trials for comparing effective doses of
the study drug? It is plausible that sponsors, in an attempt to minimize the overall clinical timeline for
drug development, were foregoing some phase II clinical trials (which are employed primarily for dose-
response studies) and instead performing more extensive investigations of dose-response behavior in
phase III trials. Decisions of this sort might push up the costs of clinical trials in the short run, as greater
numbers of arms in a study would tend to require greater numbers of patients. Furthermore, phase III
trials in general are an order of magnitude larger in patient population size than phase II trials. But in the
long run, speeding up the drug's arrival on the market might result in financial returns for the sponsor
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that would more than compensate for the additional development costs, particularly if the sponsor is in a
race with a competitor to introduce a new therapeutic.
Lastly, the observed trends toward increasing complexity could stem merely from greater
awareness on the part of pharmaceutical sponsors of the importance (from the perspective of liability) of
thoroughly testing the safety and efficacy of clinical trials prior to FDA review. Because a drug for a
chronic condition such as hypertension is designed to be taken by patients for many years, one imagines
that a sponsor would want to establish and ensure that the drug be free of serious adverse effects. If not,
the company could be open to substantial liability and loss of market share, not to mention damage to the
company's reputation.
But for a moment let me leave aside the problem of identifying the actual causes of increasing
complexity in clinical trials and instead assume, for the sake of argument, that pharmaceutical sponsors
are complicating trial design and execution of their own volition, out of a sincere desire to thoroughly
understand potential long term adverse effects on the patient population. From the perspective of public
health, would it matter if pivotal clinical trials were becoming more complex? Or put another way; even if
we assume the impulse to complicate clinical trials is motivated by beneficence, is this development in
and of itself beneficial, or cause for concern?
One approach to considering this question is to ask who benefits, and who is harmed, when
clinical trials become more complex over time. Addressing the latter first, if one assumes that increasingly
complexity could be tied to increasing costs, then one could speculate that pharmaceutical sponsors suffer
financially when clinical trials become more complicated. But as we noted above, a sponsor's investment
in higher development costs might make sense financially if it contributed to getting the drug to market
more rapidly. In broader terms, the cost of drug development is not very well correlated to the present
value of future sales of the drug.78 Instead, the price a pharmaceutical sponsor can charge for a new
therapeutic is determined predominantly by the presence or absence of competitors' drugs for the
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indication, and the real or perceived therapeutic benefit of the drug to the patient. Thus, higher
development costs will not necessarily translate into a lower return on investment for the pharmaceutical
sponsor (nor will lower development costs necessarily translate into a higher return). Given the lack of
correlation between a pharmaceutical sponsor's spending on development and its return for any
particular compound, it should follow that from the perspective of health care spending it is not clear
whether lower drug development costs would lead society to spend less on drugs.
Thus, if it is not clear anyone or any organization suffers as a result of more complicated clinical
trials, what is there to be concerned about? The issue is with the potential benefits. One might assume
that a more complex clinical trial--such as one that involves greater numbers of patients or a greater
number of arms-is necessarily providing greater insights into the safety profile and potential for causing
adverse reactions in patients. But that would only be true if the drug under investigation in a clinical trial
was meant to be prescribed in the real world for a relatively short length of time, similar to the dose
duration in the study. If, as was the case with Vioxx, some adverse events only turn up after prolonged
exposure to the drug in many patients, a more complicated clinical trial--unless it involved long-term
monitoring and follow-up--would most likely not raise any warning flags.
The upshot is that for drugs designed to treat chronic conditions such as hypertension,
complicating trials by including greater numbers of patients or arms may not cause much observable
harm, but nor does this development necessarily impart any material patient benefit. Instead, one could
argue that patients in general might be better served if pharmaceutical sponsors and the FDA shifted
their increasing emphasis on phase III trials to greater phase IV post marketing surveillance, particularly
for drugs meant to be taken for long periods of time. In this way, FDA could maintain the same threshold
for approval on the basis of phase III pivotal trials, but increase the ability to detect adverse effects that
might only become apparent after the drug is prescribed to orders of magnitude greater numbers of
people and over greater lengths of time.
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Appendix IV: Example of Inclusion/Exclusion Criteria for a Clinical Trial
Douglass et al. (1978) defined the following selection criteria for patients in a trial of chemotherapy for
advanced colorectal cancer:99
(1) Patients must have histologically confirmed metastatic or locally recurrent carcinoma of the colon
or rectum.
(2) Tumor must be beyond hope of surgical eradication.
(3) There must be tumor masses that can clearly be measured on physical examination or chest X-ray.
(4) No previous chemotherapy for their disease.
(5) An expected survival of at least 90 days and absence of severe malnutrition, nausea, and
vomiting.
(6) Patients must have recovered from effects of major surgery.
(7) Patients must have white cell count >4000 per mm3, platelet count >100,000 per mm3, hemoglobin
>10 g per 100 mL, and creatinine <1.5 mg per 100 mL.
(8) Patients must be informed of the nature of their disease and their written consent must be
obtained before instituting therapy.
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